<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended March 31, 1999
------------------------------------------------
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
--------------- -----------------------------
Commission File Number: 1-10285
---------------------------------------------------------
BIOMAGNETIC TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 95-2647755
- --------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
9727 Pacific Heights Boulevard, San Diego, California 92121-3719
- --------------------------------------------------------------------------------
(Address of principal executive offices) (zip code)
(619) 453-6300
- --------------------------------------------------------------------------------
Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name, former address and formal fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
[X] Yes [ ] No
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court. [ ] Yes [ ] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock as of the latest practicable date.
As of May 12, 1999 Registrant had only one class of common stock of
which there were 83,367,112 shares outstanding.
<PAGE>
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BIOMAGNETIC TECHNOLOGIES, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
<TABLE>
<CAPTION>
March 31, September 30,
1999 1998
--------- -------------
(Unaudited)
<S> <C> <C>
ASSETS
Cash and cash equivalents $ 381 $ 2,282
Short-term investments 7,781 10,082
Restricted cash 94 138
Accounts receivable, less allowance for
doubtful accounts of $10 1,052 932
Interest receivable 242 --
Inventories 2,833 2,991
Prepaid expenses and other 223 271
-------- --------
Total current assets 12,606 16,696
-------- --------
Net property and equipment 830 304
Restricted cash 54 187
Other assets 174 156
-------- --------
TOTAL ASSETS $ 13,664 $ 17,343
-------- --------
-------- --------
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $ 1,192 $ 783
Accrued liabilities 707 748
Accrued salaries and employee benefits 412 461
Customer deposits 1,714 2,909
Deferred revenue 679 657
-------- --------
Total current liabilities 4,704 5,558
Other long-term liabilities 15 216
-------- --------
Total liabilities 4,719 5,774
-------- --------
Commitments and Contingencies -- --
SHAREHOLDERS' EQUITY
Common stock -- no par value, 100,000,000 shares
authorized; 83,367,112 shares issued and outstanding 99,392 99,392
Additional paid-in capital 3,000 3,000
Accumulated deficit (93,447) (90,823)
-------- --------
Total shareholders' equity 8,945 11,569
-------- --------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 13,664 $ 17,343
-------- --------
-------- --------
</TABLE>
See notes to consolidated condensed financial statements.
2
<PAGE>
BIOMAGNETIC TECHNOLOGIES, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER-SHARE AMOUNTS)
(UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
March 31, March 31,
1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
REVENUES
Product $ 2,537 $ 1,520 $ 2,561 $ 1,624
Product services 99 173 191 340
Contract research 12 43 15 96
-------- -------- -------- --------
2,648 1,736 2,767 2,060
COST OF REVENUES
Product 1,217 1,168 1,486 1,276
Product services 16 39 67 147
Contract research 11 41 14 91
-------- -------- -------- --------
1,244 1,248 1,567 1,514
-------- -------- -------- --------
GROSS MARGIN 1,404 488 1,200 546
OPERATING EXPENSES
Research and development 1,336 267 1,845 676
Marketing, general and
administrative 1,050 896 2,222 1,782
-------- -------- -------- --------
2,386 1,163 4,067 2,458
-------- -------- -------- --------
OPERATING LOSS (982) (675) (2,867) (1,912)
Interest & other income (expense),
net 107 78 243 30
-------- -------- -------- --------
NET LOSS $ (875) $ (597) $ (2,624) $ (1,882)
-------- -------- -------- --------
-------- -------- -------- --------
BASIC AND DILUTED NET
LOSS PER SHARE $ (0.01) $ (0.01) $ (0.03) $ (0.04)
-------- -------- -------- --------
-------- -------- -------- --------
Weighted average number of
shares outstanding 83,367 50,522 83,367 50,522
-------- -------- -------- --------
-------- -------- -------- --------
</TABLE>
See notes to consolidated condensed financial statements.
3
<PAGE>
BIOMAGNETIC TECHNOLOGIES, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
Six Months Ended
March 31,
1999 1998
------- -------
<S> <C> <C>
OPERATING ACTIVITIES
Net loss $(2,624) $(1,882)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization 104 87
Loss on disposition of assets -- 19
Changes in operating assets and liabilities:
Restricted cash 177 371
Prepaid expenses and other 48 63
Accounts receivable (120) (344)
Inventories 158 166
Accounts payable 409 (145)
Accrued liabilities (90) (383)
Customer deposits (1,195) (63)
Deferred revenue (180) (413)
Other assets and liabilities (17) (15)
------- -------
Net cash used in operating activities (3,330) (2,539)
------- -------
INVESTING ACTIVITIES
Net change in short-term investments 2,301 --
Interest receivable (242) --
Payments for property and equipment (630) (42)
------- -------
Net cash provided by (used in) investing
activities 1,429 (42)
------- -------
FINANCING ACTIVITIES
Proceeds from notes payable to shareholder -- 870
Proceeds from issuances of common stock -- 866
------- -------
Net cash provided by financing activities -- 1,736
------- -------
NET DECREASE IN CASH AND CASH EQUIVALENTS (1,901) (845)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 2,282 1,229
------- -------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 381 $ 384
------- -------
------- -------
</TABLE>
See notes to consolidated condensed financial statements.
4
<PAGE>
BIOMAGNETIC TECHNOLOGIES, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (CONTINUED)
(IN THOUSANDS)
(UNAUDITED)
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
<TABLE>
<CAPTION>
Six Months Ended
March 31,
1999 1998
---------- ---------
<S> <C> <C>
Note payable to shareholder exchanged
for common stock $ - $ 1,700
Accrued interest on note payable to shareholder
exchanged for common stock $ - $ 38
Accounts payable to shareholder
exchanged for common stock $ - $ 219
</TABLE>
See notes to consolidated condensed financial statements.
5
<PAGE>
BIOMAGNETIC TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
1. BASIS OF PRESENTATION
The unaudited consolidated condensed financial statements of Biomagnetic
Technologies, Inc. and its subsidiary, Biomagnetic Technologies, GmbH, an
inactive wholly owned German entity, (together, the "Company", "we", "our", or
"BTi") have been prepared in accordance with the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to such
rules and regulations. The Company suggests that these financial statements be
read in conjunction with the financial statements and notes thereto included in
the Company's annual report on Form 10-K for the fiscal year ended September 30,
1998.
In the opinion of the Company, the accompanying unaudited consolidated condensed
financial statements contain all adjustments, consisting only of normal
recurring entries, necessary to present fairly its financial position at March
31, 1999 and the results of its operations and its cash flows for the periods
presented.
The preparation of financial statements, in conformity with generally accepted
accounting principles, requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from these estimates.
Certain prior period balances have been reclassified to conform to the current
period presentation.
2. BUSINESS RISKS AND UNCERTAINTIES
Biomagnetic Technologies, Inc., founded in 1970 as a California corporation, is
engaged primarily in the business of developing, manufacturing and selling
innovative functional imaging systems to medical institutions located in the
United States, Europe and Japan. The magnetic source imaging ("MSI") systems
developed by the Company measure magnetic fields created by the human body for
the noninvasive diagnosis of a broad range of disorders.
To date, the Company has been engaged principally in research and development
activities, and has made only low volume sales to medical research institutions.
The Company is currently dependent on its Magnes 2500 WH system for clinical
market sales, for which there are currently limited clinical applications.
Additional clinical applications testing needs to be conducted with the MSI
system at major clinical research centers before a substantial commercial
clinical market emerges. The Company is currently developing its Magnes 3600 WH
system, which is targeted primarily for research markets, and must continue to
depend upon sales to this market to meet its revenue goals for the very
near-term. There can be no assurance that a substantial commercial market will
develop for diagnostic or monitoring uses of the Company's MSI systems or for
the MSI industry to become viable and profitable. A continued lack of clinical
applications and commercial market for the Company's MSI systems will have a
material adverse impact on the Company's financial position, results of
operations and cash flows.
The Company's commercial success is also highly dependent on the availability of
reimbursement for procedures using the MSI system. To date, reimbursements from
third party payors are on a case-by-case basis. As of March 31, 1999, there have
been limited reimbursements from third party payors in the US. Although the
number of third party payors making reimbursements has increased, there is no
assurance that third party reimbursements will become widely available.
Reimbursements are not currently provided for MSI procedures by the United
States government, nor is there any assurance that the US government will
authorize or budget for such procedures in the future. If widespread
availability of reimbursement from the government and private insurers is not
achieved, the Company's financial position, results of operations and cash flows
would be materially adversely affected. The Company also cannot predict what
legislation relating to its business or the health care industry may be enacted
in the future, including legislation relating to third party reimbursement, or
what effect such legislation may have on its financial position, results of
operations and cash flows.
6
<PAGE>
The industry in which the Company operates is characterized by rapid
technological change. New products using other technologies or improvements to
existing products may reduce the size of the potential markets for the Company's
products, and may render them obsolete or non-competitive. Competitors may
develop new or different products using technology or imaging modalities that
may provide or be perceived as providing greater value than the Company's
products. Any such development could have a material adverse effect on the
Company's financial position, results of operations and cash flows.
Additionally, there has been recently, and continues to be, ongoing significant
price competition from the Company's competitors for the currently limited
number of whole head systems being purchased worldwide. This aggressive
competition may affect future profitability of the Company, the extent of which
is not presently determinable.
For the quarter ended March 31, 1999, the Company incurred a net loss of
$875,000 and had negative cash flows from operations of $1,187,000. At March 31,
1999, the Company has an accumulated deficit of $93,447,000, net capital of
$8,945,000 and working capital of $7,902,000. The Company anticipates that in
fiscal 1999, operating and working capital requirements will substantially
exceed cash projected to be generated by product sales.
Based on its current operating plans, including anticipated product orders and
resulting revenues and cash receipts capital expenditures, expected working
capital requirements and existing capital resources, the Company anticipates
that it will be able to fund its operations through the second quarter of fiscal
2000. The realization of the Company's operating plans is dependent upon its
ability to successfully close a number of MSI system sales in the current highly
competitive market for the limited number of systems being purchased worldwide.
There can be no assurance that sufficient sales of the Company's Magnes systems
will be achieved in order to realize its current operating plans. If these
revenues are not achieved, the Company believes its existing capital resources
as of March 31, 1999 will be sufficient to meet its obligations through calendar
1999 only. In either case, the Company must continue to fund its operating
needs, and is currently considering a number of financing alternatives, such as
corporate partnerships and the sale of equity or debt securities. There can be
no assurance that such financing will be available on terms acceptable to the
Company, if at all.
Additional risks and uncertainties include, but are not limited to, satisfying
customer performance requirements for our systems, unfavorable medical industry
trends, increased government regulations and requirements, foreign exchange
risks and Year 2000 issues. The reader is encouraged to refer to the Company's
other Securities and Exchange Commission filings, including its most recent Form
10-K, to ascertain the extent and magnitude of these and other risks and
uncertainties the Company may encounter.
3. FINANCING
In August 1998, the Company received total proceeds of $15,000,000 from the sale
of 30,000,000 unregistered shares of common stock at $.50 per share to offshore
investors pursuant to Regulation S. Dassesta International S.A., a major
shareholder of BTi since March 1995 purchased 10,000,000 shares. "La Caixa",
Caja de Ahorros y Pensiones de Barcelona, one of the leading financial
institutions of the Kingdom of Spain purchased 10,000,000 shares. A total of
2,000,000 shares were sold to Swisspartners Investment Network LTD, and the
remaining 8,000,000 shares were purchased by two European banks under the same
terms and conditions.
As of July 1998, the Company had borrowed $2,000,000 from Dassesta
International, S.A. The loan was a 180 day unsecured loan bearing interest at
8%. In August 1998, the Company paid off the total principal of $2,000,000 owed
to Dassesta plus $36,000 of related accrued interest using proceeds from the
August 1998 financing of $15,000,000.
4. BASIC AND DILUTED NET LOSS PER SHARE
Shares used in computing basic and diluted net loss per share include the
weighted average number of common shares outstanding. Common stock equivalents
are antidilutive and are excluded from the computation of basic and diluted net
loss per share.
7
<PAGE>
5. INVENTORIES
The composition of inventories is as follows:
<TABLE>
<CAPTION>
March 31, September 30,
1999 1998
------ ------
<S> <C> <C>
Raw materials $ 132 $ 163
Work-in process 2,701 2,328
Finished goods -- 500
------ ------
$2,833 $2,991
------ ------
------ ------
</TABLE>
The Company regularly evaluates the composition of its inventories and has
established reserves for estimated obsolete and excess inventories. The values
presented on the Company's most recent balance sheets are net of these reserve
estimates.
6. CUSTOMER BACKLOG AND DELIVERY RISK
The Company's backlog at March 31, 1999 amounted to $2,852,000 and is composed
primarily of orders for a 248 channel Magnes 3600 WH system, a Magnes 1300 C
cardiac system and research contracts. Future cash payments to the Company
pertaining to backlog beyond cash deposits already received as of March 31, 1999
total approximately $819,000. As sales of the Company's systems typically
involve transactions of $1 million or more, the backlog is expected to fluctuate
significantly from fiscal period to fiscal period depending upon timing of
orders received, installations completed, and customer acceptances received
during the reporting period.
7. SEGMENT INFORMATION
The Company operates in one segment that includes developing, manufacturing and
selling magnetic source imaging products. The overall market for the Company's
operations can be further divided into three overlapping sub-segments: the basic
research market, the applications research market, and the commercial clinical
market. To date, substantially all of the Company's revenues have been derived
from, and substantially all of the Company's assets have been devoted to, the
basic research market.
8. COMPREHENSIVE INCOME
The Company has no components of comprehensive income.
9. RECENT ACCOUNTING PRONOUNCEMENTS
In March 1998, the Accounting Standards Executive Committee (AcSEC) issued AICPA
Statement of Position (SOP) 98-1, "Accounting for Costs of Computer Software
Developed or Obtained for Internal Use." This statement provides guidance on
accounting for the costs of computer software developed or obtained for internal
use and identifies characteristics of internal-use software and provides
assistance in determining when computer software is for internal use. SOP 98-1
is effective for fiscal years beginning after December 15, 1998, with earlier
application permitted. The Company does not anticipate the adoption of SOP 98-1
having a material impact on the Company's financial position of results of
operations.
In April 1998, AcSEC issued AICPA SOP 98-5, "Reporting on the Costs of Start-Up
Activities." This statement provides guidance on financial reporting of start -
up costs and organization costs and requires that such costs of start-up
activities be expensed as incurred. SOP 98-5 is effective for fiscal years
beginning after December 15, 1998, with earlier application permitted. The
Company does not anticipate the adoption of SOP 98-5 having a material impact on
the Company's financial position or results of operations.
10. SUBSEQUENT EVENTS
The Company has recently entered into clinical research agreements with three
medical institutions. Under the terms of the agreements, the Company will
reimburse an aggregate of approximately $400,000 to the institutions for costs
incurred related to operation of, and research performed with, the Company's MSI
systems.
8
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Except for the historical information contained herein, the following discussion
may contain (and the Notes to the Consolidated Condensed Financial Statements
may contain) forward-looking statements that involve risks and uncertainties.
The Company's future results could differ materially from those discussed here.
Factors that could cause or contribute to such differences include, but are not
specifically limited to those discussed in "Risks and Uncertainties" below. The
Company does not undertake to update the statements discussed herein as a result
of changes in risks or operating results.
OVERVIEW
Since 1984, the primary business of the Company has been the development of MSI
systems that measure magnetic fields generated by the human body and assist in
the noninvasive diagnosis of a broad range of medical disorders. The measurement
of the body's magnetic fields by MSI provides information about the normal and
abnormal functions of the brain, heart and other organs. The Company is focusing
on the development of its technology for potential commercial market
applications such as mapping of functional cortex at risk during surgery for
tumors and other lesions, and the diagnosis and planning for surgical treatment
of epilepsy. The Company is continuing to investigate the potential applications
of its technology for problems of the heart, spine, and gastrointestinal system,
as well as for disorders of the brain such as closed-head trauma, schizophrenia
and other neuro-psychiatric disorders. To date, the Company, its competitors and
the market have identified only a limited number of diagnostic applications for
MSI systems.
Twenty four (24) Magnes systems were installed in medical and research
institutions worldwide as of March 31, 1999. To date, more than 5,000 MSI
examinations have been performed on patients and control subjects at the
Company's application development sites. Related findings by BTi and its
collaborators have been published in more than 75 scientific and medical papers.
Since the first reimbursement for MSI procedures was received in September 1993,
more than 140 insurance companies have approved reimbursement on a case-by-case
basis for certain MSI procedures performed with the Company's Magnes MSI
systems.
In fiscal 1995, BTi announced development of the Magnes 2500 WH, an expansion of
the existing Magnes I and Magnes II systems product line. Development of the
Magnes 2500 WH hardware was substantially completed in fiscal year 1996. The
Magnes 2500 WH allows simultaneous examination of the entire brain and is
designed for evaluating ambulatory or critically ill patients in seated or fully
reclined positions. As of March 31, 1999, the Company has sold eleven Magnes
2500 WH systems.
In fiscal 1998 the Company commenced the development of the Magnes 3600 WH. This
system entered development in response to a continuing need in the research
market for increased sensitivity and deep body imaging, as well as competitive
pressures. BTi expects delivery of its first 3600 WH to a Japanese customer
during the Company's fiscal fourth quarter.
The current price of BTI's MSI systems ranges from approximately $1.0 to $2.5
million, depending upon system configuration. A significant portion of the
Company's sales have been, and are expected to continue to be, in foreign
markets. The Company has previously priced certain of its European sales in the
currency of the country in which the product was sold and the prices of such
products in dollars varied as the value of the dollar fluctuated against the
quoted foreign currency price. There can be no assurance that currency
fluctuations will not reduce the dollar return to the Company on such sales if
made in the future. At March 31, 1999 and September 30, 1998, the Company did
not have any open forward exchange contracts. The Company may in the future
enter into forward exchange contracts to partially hedge such foreign currency
exposure, if appropriate.
Due to substantial research and development expenses and low unit sales, the
Company has historically reported net losses. Research and development
expenditures have increased significantly since capital funding was received in
August 1998. Such expenditures may continue to increase in the future as new
products enter into development, and Company sponsored clinical testing is
performed to establish a baseline of data for reimbursement approvals and for
substantiating new applications for MSI systems.
9
<PAGE>
The Company believes that the relatively small number of proven medical
applications for the Magnes systems, the lack of routine reimbursement for MSI
procedures, and the uncertainty of product acceptance in the U.S. market have
limited system sales through March 31, 1999. Additionally, it is not possible to
reliably predict the timing and extent of future product sales due to the
uncertainties of medical applications, reimbursement and product acceptance. The
Company does not anticipate multiple sales to the same end-user at current sales
volumes, and the sale of one Magnes system may have a significant impact on the
Company's financial position and results of operations during any reporting
period. As a result, quarterly and annual operating performance will continue to
fluctuate.
RESULTS OF OPERATIONS
Total revenues for the second quarter of fiscal 1999 were $2,648,000 including
$99,000 of service revenues, compared to $1,736,000 of total revenues, including
$173,000 of service revenues, for the second quarter of fiscal 1998. Increased
total revenues is attributed to the revenue recognition of two 2500 WH systems
and one Magnes I system in the second quarter of fiscal 1999. The decrease in
service revenues reflects a decrease in the amount of service contracts in
effect during this time period. Total revenues for the first six months of
fiscal 1999 were $2,767,000 including $191,000 of service revenues, compared to
$2,060,000 of total revenues, including $340,000 of service revenues for the
first six months of fiscal 1998.
Research and development expenses amounted to $1,336,000 and $1,845,000 for the
three month and six month periods ended March 31, 1999. These amounts
represented an increase of 500% for the quarter and 273% for the six month
period compared to research and development expenses of $267,000 and $676,000
for the same periods in fiscal 1998. These increases are primarily due to
development efforts for software and hardware enhancements to the Magnes 2500
WH, the construction of product engineering testing equipment, support of the
epilepsy clinical testing program at two research clinics in the US, and ongoing
development of the Magnes 3600 WH system. Further, the fiscal 1998 periods
reflected reductions in project spending and research staff attributable to very
limited cash resources.
Marketing, general and administrative expenses increased by $154,000 to
$1,050,000 for the second quarter of fiscal 1999, a 17% increase versus the
comparable period in fiscal 1998. For the first six months of fiscal 1999, such
expenses increased by $440,000 to $2,222,000, a 20% increase as compared to the
same period last fiscal year. These increases are primarily attributable to
increased marketing communication expenses, the addition of sales personnel and
related sales activities, and increased consulting costs.
Interest income totaled $242,000 during the six months ended March 31, 1999 as
compared to $30,000 during the comparable period in fiscal 1998. The increase is
the result of investing excess cash generated from the August 1998 financing,
described below in "Liquidity and Capital Resources".
Net loss in the second quarter of fiscal 1999 amounted to $875,000 compared to a
net loss of $597,000 for the comparable period in the prior fiscal year. Net
loss for the six months ended March 31, 1999 was $2,624,000 as compared to
$1,882,000, for the comparable period last fiscal year. The increased net loss
for the six month period was primarily due to the increase in research and
development costs and increased marketing and general and administrative costs.
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 1999 the Company has working capital of $7,902,000. At September
30, 1998, the Company's working capital was $11,138,000. Cash and cash
equivalents and short-term investments decreased $4,202,000 to $8,162,000 at
March 31, 1999 as compared to $12,364,000 at September 30, 1998. The decline in
cash primarily reflects the use of working capital to fund operations and to
purchase and construct capital equipment for use in the epilepsy clinical
expansion program.
Capital equipment expenditures totaled $630,000 for the second quarter of fiscal
1999, compared with $42,000 for the same period in fiscal 1998. The increase was
due primarily to the construction of a 2500 WH system for use in the epilepsy
clinical testing program and the purchase of computer equipment to replace
existing outdated equipment.
10
<PAGE>
The Company has recently entered into clinical research agreements with three
medical institutions. Under the terms of the agreements, the Company will
reimburse an aggregate of approximately $400,000 to the institutions for costs
incurred related to operation of, and research performed with, the Company's MSI
systems.
The Company anticipates that in fiscal 1999 operating and working capital
requirements will substantially exceed cash projected to be generated by product
sales. Historically, the Company has offset this deficit by raising capital
funds from private placements of its common stock and from debt offerings. The
Company anticipates that it will continue to incur operating losses for the
foreseeable future, until market acceptance of MSI applications and
corresponding product sales are sufficient to generate continuing profits.
In August 1998 the Company received $15,000,000 in proceeds from the sale of
30,000,000 shares of unregistered common stock at $.50 per share to offshore
investors pursuant to Regulation S. Dassesta International S.A. ("Dassesta"), a
major shareholder of the Company since March 1995, purchased 10,000,000 shares,
"La Caixa", Caja de Ahorras y Pensiones de Barcelona, one of the leading
financial institution of the Kingdom of Spain, purchased 10,000,000 shares. A
total of 2,000,000 shares were sold to Swisspartners Investment Network LTD, and
the remaining 8,000,000 shares were purchased by two European banks under the
same terms and conditions.
From January to July 1998 the Company had borrowed a total of $2,000,000 from
Dassesta for working capital requirements. In August 1998, out of the proceeds
received from the above offering, the Company paid off the Dassesta principal,
plus $36,000 of accrued interest.
In December 1997, the Company sold 4,000,000 unregistered shares of common stock
to Dassesta and an additional 1,500,000 unregistered shares of common stock to
Bank Leu under Regulation S at $.50 per share. Consideration received by the
Company for the sale consisted of cash totaling $793,000 and cancellation of its
then outstanding loan principal of $1,700,000, related accrued interest of
$38,000 and accounts payable of $219,000, all owed to Dassesta.
Based on its current operating plans, including anticipated product orders and
resulting revenues and cash receipts, capital expenditures, expected working
capital requirements and existing capital resources, the Company anticipates
that it will be able to fund operations through the second quarter of fiscal
2000. The realization of the Company's operating plans is dependent upon its
ability to successfully close a number of MSI system sales in the current highly
competitive market for the limited number of systems being purchased worldwide.
There can be no assurance that sufficient sales of the Company's Magnes systems
will be achieved in order to realize its current operating plans. If these
revenues are not achieved, the Company believes its existing capital resources
as of March 31, 1999 will be sufficient to meet its obligations through calendar
1999 only. In either case, the Company must continue to fund its operating
needs, and is currently considering a number of financing alternatives, such as
corporate partnerships and the sale of equity or debt securities. There can be
no assurance that such financing will be available on terms acceptable to the
Company, if at all.
YEAR 2000 ASSESSMENT
Many currently installed computer systems and software products are coded to
accept only 2 digit entries in the date code field. Beginning in the year 2000,
these date code fields will need to accept 4 digit entries to distinguish 21st
century dates from the 20th century dates. Systems that do not properly
recognize such information could generate erroneous data or cause a system to
fail. As a result, computer systems, software and industrial controls used by
many companies may need to be upgraded to comply with Year 2000 requirements.
We are utilizing both internal and external resources to identify, correct or
reprogram, and test our internal systems for Year 2000 compliance. We have
determined that it is necessary to acquire new Year 2000 compliant computer
hardware and software systems for our accounting, purchasing, production control
and inventory management systems. Also, our security system and portions of our
telephone system must be upgraded.
We are currently seeking to ensure that the software and operating systems
included in our Magnes systems are Year 2000 compliant. Our current testing has
indicated that earlier models of our products were purchased from us using
computer hardware and software that requires modification or replacement. We are
developing a new version of our software that when combined with a new computer
and operating system should be Year 2000 compliant; we expect to make this
solution available by June 1999 to our customers that have earlier models. Our
current Magnes 2500 WH product has been tested and customer systems in the field
should not require modification.
11
<PAGE>
We are also in the process of requesting information and assurances from our
major vendors, service providers and customers about their state of Year 2000
compliance and readiness. In the event that significant Year 2000 issues are
identified with such parties, we will identify contingency plans such as the use
of alternate vendors or manual systems.
Current estimates of total costs of Year 2000 compliance amount to approximately
$350,000, including internal and external hardware, software and labor costs for
systems implementation and testing. Installation, replacement and updating of
these systems is currently in process. It is estimated that installation,
replacement and updating will be completed by June 1999, and testing will be
ongoing through September 1999 and completed by December 1999.
If our systems are not made compliant by year-end it could significantly
adversely affect our sales. Year 2000 issues could cause potential customers to
reevaluate their current needs and consider deferring purchase of our Magnes
systems or decide to purchase from a competitor. Additionally, we could have
potential warranty or other claims with existing Magnes systems placed with
customers if such systems are not made Year 2000 compliant. Any of the foregoing
could result in a material adverse effect on our business, financial position
and results of operations.
ADDITIONAL RISKS AND UNCERTAINTIES
WE EXPECT CONTINUED OPERATING LOSSES.
Our financial position reflects that we have been principally focused on
research and development, with only low volume sales to medical research
institutions. For the first six months of fiscal 1999, our net loss was
$2,624,000 and we had negative cash flows from operations of $3,330,000.
At March 31, 1999, our accumulated deficit was $93,447,000 with working capital
of $7,902,000. Our cash balance at March 31, 1999 was $8,162,000. This balance
reflects the sale during August 1998 of 30,000,000 shares of common stock for
proceeds of $15,000,000, and the sale of two 2500 WH systems and the sale of one
Magnes I system, less usage of cash from ongoing operations.
We anticipate that in fiscal 1999 we will incur a net loss from operations, and
cash usage will substantially exceed that projected to be received from product
sales.
OUR SUCCESS MAY BE LIMITED BY OUR ABILITY TO SATISFY CUSTOMER PERFORMANCE
REQUIREMENTS.
Our success may be limited by our ability to complete, in a timely fashion,
product developments and enhancements to satisfy customer requirements for our
systems.
OUR SUCCESS MAY BE LIMITED BY OUR DEPENDENCE UPON A SINGLE PRODUCT AND
UNCERTAINTY WITH RESPECT TO THE DEVELOPMENT OF ADDITIONAL PRODUCTS.
Our success may be limited by our dependence on our one current product, the
Magnes 2500 WH system. Before we can more fully penetrate the research and
commercial markets, we need to have additional products. In development is our
Magnes 3600 WH, which is intended to address more fully the needs of research
institutions. Our Magnes 2500 WH system is more appropriate for the commercial
market. Our financial results will be materially adversely affected if our
Magnes 2500 WH system does not suit the majority of commercial applications that
emerge, or we are not able to offer new products in a timely and cost effective
manner that meet the emerging needs of the marketplace.
OUR SUCCESS HAS BEEN LIMITED BY A LACK OF CURRENTLY IDENTIFIED CLINICAL
APPLICATIONS FOR MSI SYSTEMS.
Currently, there are only a few established diagnostic uses for MSI systems that
the medical industry is aware of. Although we have started our own clinical
research and testing to identify new, large application areas, we cannot assure
you that a commercial market will develop for multiple uses of our products.
12
<PAGE>
OUR SUCCESS MAY BE LIMITED BY OUR DEPENDENCY ON AND UNCERTAINTY WITH RESPECT TO
THIRD PARTY REIMBURSEMENT AND HEALTHCARE REFORM.
Our commercial success is also highly dependent on reimbursement for procedures
using the MSI system. Currently, Medicare, insurance companies and other
healthcare providers approve payment for MSI procedures on a case-by-case basis.
As of March 31, 1999, these third party payors have only approved limited
reimbursements in the United States. Although third party payors have
increasingly approved reimbursements, we cannot assure you that third party
reimbursements will become widely available. The United States government does
not currently reimburse for MSI procedures. If reimbursement does not become
more widely available, our financial position will be materially adversely
affected. In addition, there is currently no reimbursement for MSI procedures
outside of the United States.
OUR PRODUCTS AND TECHNOLOGY MAY BECOME OBSOLETE.
Our industry is characterized by rapid technological change, which may also
impact our commercial success. Competitors may develop products using other
technologies or may improve existing products. This competition may reduce the
size of the potential market for our products or make them obsolete or
non-competitive. Competitors may also develop new or different products using
technology or imaging modalities that provide, or are perceived as providing,
greater value than the Company's products. Our financial position will be
materially adversely affected if such competitive developments occur.
WE MAY BE NEGATIVELY IMPACTED BY AGGRESSIVE COMPETITION IN OUR INDUSTRY.
Our industry is characterized by ongoing significant price competition, due to
the existence of a number of competitors in a fledgling marketplace with a
limited number of MSI systems being purchased worldwide. The future
profitability of our systems may be negatively impacted by this aggressive
competition; we currently cannot predict how rapidly the market may expand to
provide MSI system manufacturers with appropriate shareholder returns.
NEW GOVERNMENT LEGISLATION AND UNFAVORABLE MEDICAL INDUSTRY TRENDS MAY ADVERSELY
IMPACT US.
We cannot predict what adverse effect, if any, future legislation or Food and
Drug Administration regulations may have on the MSI market and our financial
results. Medical industry cost containment trends may impose restrictions on
sizeable third-party reimbursements for diagnostic procedures, limiting the
market opportunity. Further, if Federal government agencies or any state
legislature enacts legislation or guidelines relating to our business or the
health care industry that create additional business hurdles, including
legislation relating to third party reimbursement, our financial position could
be negatively affected.
OUR BUSINESS ACTIVITIES MAY INVOLVE FOREIGN EXCHANGE RELATED RISKS.
Because we sell in foreign markets, we are exposed to potential risks of
increases and decreases in foreign currency exchange rates. When appropriate, we
enter into forward exchange contracts to partially hedge (or protect) against
such foreign currency exchange fluctuations. Nonetheless, these fluctuations may
reduce the return in U.S. dollars that we actually receive on our sales. These
risks may become material as our sales increase or dramatic currency
fluctuations occur from outside events.
FAILURE TO BE YEAR 2000 COMPLIANT COULD HARM OUR BUSINESS.
For risks relative to Year 2000 issues, please see "Management's Discussion and
Analysis of Financial Condition and Results of Operations - Year 2000
Assessment".
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
None.
13
<PAGE>
PART II. OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The Company held its Annual Meeting of Shareholders on March 19, 1999 and
proxies for such meeting were solicited pursuant to Regulation 14A. There was
no solicitation in opposition to the Company's nominees for directors as listed
in the proxy statement and all such nominees were elected. In addition, the
following matters were adopted by the Shareholders at the Annual Meeting.
(a) For the election of Nominees to the Board of Directors for the
fiscal year ending September 30, 1999.
<TABLE>
<CAPTION>
Nominee For Against Non-votes
------- --- ------- ---------
<S> <C> <C> <C>
D. Scott Buchanan 73,497,063 67,910 0
Martin P. Egli 73,497,063 67,910 0
Galleon Graetz 73,497,063 67,910 0
Rodolfo Llinas 73,497,063 67,910 0
Enrique Maso 73,497,063 -
</TABLE>
(b) Ratify the selection of Arthur Andersen LLP as independent
accountants for the fiscal year ending September 30, 1999.
<TABLE>
<S> <C> <C> <C> <C>
For - 73,520,649 Against - 18,050 Abstain - 26,274 Broker Non-Votes - 0
</TABLE>
(c) Amend the Company's Articles of Incorporation to increase the
number of authorized shares of Common Stock from 100,000,000
to 200,000,000 shares.
<TABLE>
<S> <C> <C> <C> <C>
For - 73,226,972 Against - 277,901 Abstain - 60,100 Broker Non-Votes - 0
</TABLE>
(d) Amend the 1997 Stock Incentive Plan to increase the number of
shares of Common Stock from 3,000,000 to 6,000,000 shares.
<TABLE>
<S> <C> <C> <C> <C>
For - 72,149,763 Against - 345,567 Abstain - 108,965 Broker Non-Votes - 960,678
</TABLE>
ITEM 5. OTHER INFORMATION
None.
14
<PAGE>
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
<TABLE>
<CAPTION>
a) EXHIBIT NO. DESCRIPTION
<S> <C>
3.1 Form of Certificate of Amendment of
Fourth Restated Articles of
Incorporation to be filed with the
California Secretary of State.
3.2 Fourth Restated Articles of Incorporation, as
amended.
3.3 Restated By-laws.
27 Financial Data Schedule
</TABLE>
b) Reports on Form 8-K.
None.
15
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BIOMAGNETIC TECHNOLOGIES, INC.
May 14, 1999 /s/ D. SCOTT BUCHANAN
- ------------------------- ------------------------------------------
Date D. Scott Buchanan
President and Chief Executive Officer
May 14, 1999 /s/ ARON P. STERN
- ------------------------- -------------------------------------------
Date Aron P. Stern
Vice President of Finance, Chief Financial
Officer Secretary
Principal Financial and Accounting Officer
16
<PAGE>
CERTIFICATE OF AMENDMENT
OF
FOURTH RESTATED ARTICLES OF INCORPORATION, AS AMENDED
D. Scott Buchanan and Aron P. Stern hereby certify that:
1. They are the President and the Secretary, respectively, of Biomagnetic
Technologies, Inc., a California corporation (the "Corporation").
2. Article IV of the Fourth Restated Articles of Incorporation, as
amended, (the "Articles") of the Corporation is amended to read as
follows:
"The corporation is authorized to issue one (1) class of stock to be
designated "Common Stock." The total number of shares which the
corporation is authorized to issue is Two Hundred Million (200,000,000)
shares, of which all such shares shall be Common Stock, without par
value."
3. The foregoing amendment of the Articles has been duly approved by the
Board of Directors.
4. The foregoing amendment of the Articles has been duly approved by the
required vote of shareholders in accordance with Sections 902 and 903
of the California Corporations Code. The total number of outstanding
shares of the Corporation entitled to vote with respect to this
amendment was 83,367,112 shares of Common Stock. The number of shares
voting in favor of the amendment equaled or exceeded the vote required.
The percentage vote required was more than 50 percent of all
outstanding shares of Common Stock.
We further declare under penalty of perjury under the laws of the State of
California that the matters set forth in this certificate are true and
correct of my own knowledge.
DATED: May 14, 1999
/s/ D. Scott Buchanan
------------------------------------
President
/s/ Aron P. Stern
------------------------------------
Secretary
<PAGE>
FOURTH RESTATED ARTICLES OF INCORPORATION
OF
BIOMAGNETIC TECHNOLOGIES, INC.,
a California Corporation
William L. Stephan and Eugene C. Hirschkoff certify that:
1. They are the Vice President and the Secretary, respectively, of
Biomagnetic Technologies, Inc., a California corporation.
2. The Articles of Incorporation of said corporation shall be amended
and restated to read in full as follows:
ARTICLE I
The name of the the corporation is BIOMAGNETIC TECHNOLOGIES, INC.
ARTICLE II
The purpose of the corporation is to engage in any lawful act or
activity for which a corporation may be organized under the General
Corporation Law of California other than the banking business, the trust
company business or the practice of a profession permitted to be
incorporated by the California Corporations Code.
ARTICLE III
The corporation elects to be governed by all the provisions of the
General Corporation Law (as added to the California Corporations Code
effective January 1, 1977, and as subsequently amended) not otherwise
applicable to this corporation under Chapter 23 of said General
Corporation Law.
ARTICLE IV
The corporation is authorized to issue only one class of shares of
Common Stock; and the total number of shares of Common Stock which this
corporation is authorized to issue is twenty-three million (23,000,000)
shares without par value.
<PAGE>
ARTICLE V
Section 1. The liability of the directors of the corporation for
monetary damages shall be eliminated to the fullest extent permissible
under California law.
Section 2. This corporation is authorized to indemnify the
directors and officers of this corporation to the fullest extent
permissible under California law.
Section 3. The corporation is authorized to provide indemnification
of agents (as defined in Section 317 of the California Corporations
Code) through bylaw provisions, agreements with agents, vote of
shareholders or disinterested directors or otherwise, in excess of the
indemnification otherwise permitted by Section 317 of the California
Corporations Code, subject only to applicable limits set forth in
Section 204 of the California Corporations Code with respect to actions
for breach of duty to the corporation and its shareholders.
3. The foregoing amendment and restatement of Articles of Incorporation
has been duly approved by the Board of Directors of said corporation.
4. The foregoing amendment and restatement of Articles of Incorporation
has been duly approved by the holders of the requisite number of shares of
said corporation in accordance with Section 903 of the California General
Corporation Law. The total number of outstanding shares entitled to vote with
respect to the foregoing amendment was 5,624,890 shares of stock. The number
of shares voting in favor of the foregoing amendment and restatement equaled
or exceeded the vote required, such required vote being a majority of the
outstanding shares of stock.
We declare under penalty of perjury under the laws of the State of
California that the matters set forth in this Certificate are true and
correct of our own knowledge.
Date: February 21, 1990
/s/ William L. Stephan
-----------------------------------
William L. Stephan,
Vice President
/s/ Eugene C. Hirschkoff
-----------------------------------
Eugene C. Hirschkoff,
Secretary
<PAGE>
CERTIFICATE OF AMENDMENT
OF
FOURTH RESTATED ARTICLES OF INCORPORATION
James. V. Schumacher and Peter L. Millikin hereby certify that:
1. They are the President and Chief Executive Officer and Secretary,
respectively of Biomagnetic Technologies, Inc., a California corporation.
2. Article IV of the Fourth Restated Articles of Incorporation of this
corporation is amended to read as follows:
"The corporation is authorized to issue one (1) class of
stock to be designated "Common Stock." The total number of
shares which the corporation is authorized to issue is
Sixty Million (60,000,000) shares, of which all such
shares shall be Common Stock, without par value."
3. The foregoing amendment of Fourth Restated Articles of Incorporation
has been duly approved by the board of directors.
4. The foregoing amendment of Fourth Restated Articles of
Incorporation has been duly approved by the required vote of shareholders in
accordance with Sections 902 and 903 of the California Corporations Code. The
current total number of outstanding shares of the corporation is 10,027,697
shares of Common Stock. The number of shares voting in favor of the amendment
equaled or exceeded the vote required. The percentage vote required was more
than 50 percent of all outstanding shares of Common Stock.
We further declare under penalty of perjury under the laws of the State
of California that the matters set forth in this certificate are true and
correct of my own knowledge.
DATED: March 24, 1995
/s/ James V. Schumacher
-----------------------------------
President and Chief Executive
Officer
/s/ Peter L. Millikin
-----------------------------------
Secretary
<PAGE>
CERTIFICATE OF AMENDMENT
OF
FOURTH RESTATED ARTICLES OF INCORPORATION, AS AMENDED
D. Scott Buchanan and Herman Bergman hereby certify that:
1. They are the President and the Secretary, respectively, of
Biomagnetic Technologies, Inc., a California corporation (the "Corporation").
2. Article IV of the Fourth Restated Articles of Incorporation, as
amended, (the "Articles") of the Corporation is amended to read as follows:
"The corporation is authorized to issue one (1) class of
stock to be designated "Common Stock." The total number of
shares which the corporation is authorized to issue is One
Hundred Million (100,000,000) shares, of which all such
shares shall be Common Stock, without par value."
3. The foregoing amendment of the Articles has been duly approved by
the board of directors.
4. The foregoing amendment of the Articles has been duly approved by
the required vote of shareholders in accordance with Sections 902 and 903 of
the California Corporations Code. The current total number of outstanding
shares of the Corporation is 47,691,824 shares of Common Stock. The number of
shares voting in favor of the amendment equaled or exceeded the vote
required. The percentage vote required was more than 50 percent of all
outstanding shares of Common Stock.
We further declare under penalty of perjury under the laws of the State
of California that the matters set forth in this certificate are true and
correct of my own knowledge.
DATED: March 19, 1997
/s/ D. Scott Buchanan
-----------------------------------
President
/s/ Herman Bergman
-----------------------------------
Secretary
<PAGE>
R E S T A T E D
B Y L A W S
OF
BIOMAGNETIC TECHNOLOGIES, INC.
a California Corporation
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
ARTICLE I MEETINGS OF SHAREHOLDERS........................................... 1
Section 1. ANNUAL MEETINGS............................................... 1
Section 2. SPECIAL MEETINGS.............................................. 1
Section 3. NOTICE........................................................ 1
Section 4. ADJOURNED MEETING AND NOTICE THEREOF.......................... 2
Section 5. QUORUM........................................................ 3
Section 6. CONSENT OF ABSENTEES.......................................... 3
Section 7. ACTION WITHOUT MEETING........................................ 3
Section 8. RECORD DATES.................................................. 4
Section 9. PROXIES....................................................... 5
Section 10. VOTING; CUMULATIVE VOTING AND NOTICE THEREOF.................. 5
Section 11. CHAIRMAN OF MEETING........................................... 6
Section 12. INSPECTORS OF ELECTION........................................ 6
ARTICLE II DIRECTORS.......................................................... 7
Section 1. POWERS........................................................ 7
Section 2. NUMBER........................................................ 7
Section 3. ELECTION AND TERM OF OFFICE................................... 7
Section 4. ORGANIZATION MEETING.......................................... 8
Section 5. REGULAR MEETINGS.............................................. 8
Section 6. SPECIAL MEETINGS.............................................. 8
Section 7. NOTICE OF MEETINGS............................................ 8
Section 8. PARTICIPATION BY TELEPHONE.................................... 8
Section 9. QUORUM........................................................ 8
Section 10. VOTING........................................................ 9
Section 11. ACTION WITHOUT MEETING........................................ 9
Section 12. VALIDATION OF MEETING......................................... 9
Section 13. RESIGNATION................................................... 9
Section 14. VACANCIES..................................................... 9
Section 15. ADJOURNMENT................................................... 10
Section 16. VISITORS...................................................... 10
Section 17. FEES AND COMPENSATION......................................... 10
Section 18. COMMITTEES.................................................... 10
Section 19. MEETINGS AND ACTION OF COMMITTEES............................. 11
ARTICLE III OFFICERS........................................................... 11
Section 1. OFFICERS...................................................... 11
Section 2. ELECTION...................................................... 11
Section 3. SUBORDINATE OFFICERS.......................................... 12
Section 4. REMOVAL AND RESIGNATION....................................... 12
Section 5. VACANCIES..................................................... 12
Section 6. CHAIRMAN OF THE BOARD......................................... 12
Section 7. PRESIDENT..................................................... 12
Section 8. VICE PRESIDENT................................................ 13
Section 9. SECRETARY..................................................... 13
Section 10. CHIEF FINANCIAL OFFICER....................................... 13
-i-
<PAGE>
ARTICLE IV MISCELLANEOUS...................................................... 14
Section 1. LOANS TO OR GUARANTIES FOR THE BENEFIT OF OFFICERS OR
DIRECTORS; LOANS UPON THE SECURITY OF SHARES OF THE
CORPORATION................................................... 14
Section 2. RECORD DATE AND CLOSING STOCK BOOKS........................... 15
Section 3. INSPECTION OF CORPORATE RECORDS............................... 15
Section 4. EXECUTION OF CONTRACTS........................................ 15
Section 5. SHARE CERTIFICATES............................................ 16
Section 6. REPRESENTATION OF SECURITIES OF OTHERS........................ 17
Section 7. INSPECTION OF BYLAWS.......................................... 17
Section 8. EMPLOYEE STOCK PURCHASE AND OPTION PLANS...................... 17
Section 9. CONSTRUCTION AND DEFINITIONS.................................. 17
Section 10. INDEMNIFICATION OF CORPORATE AGENTS........................... 17
Section 11. FINANCIAL STATEMENTS.......................................... 18
Section 12. CHECKS, DRAFTS, EVIDENCE OF INDEBTEDNESS...................... 18
ARTICLE V AMENDMENTS TO BYLAWS............................................... 19
Section 1. POWER OF SHAREHOLDERS......................................... 19
Section 2. EFFECTIVE DATE................................................ 19
</TABLE>
-ii-
<PAGE>
B Y L A W S
Bylaws for the regulation, except as otherwise provided by statute or its
Articles of Incorporation ("Articles"), of
BIOMAGNETIC TECHNOLOGIES, INC.
(a California Corporation)
ARTICLE I
MEETINGS OF SHAREHOLDERS
Section 1. ANNUAL MEETINGS. The annual meeting of shareholders shall be held
between 60 and 180 days following the end of the fiscal year of the
corporation and at such precise date and time and at such place as fixed by
the resolution of the Board of Directors ("Board"). At such meeting,
directors shall be elected, reports of the affairs of the corporation shall
be considered, and any other business may be transacted which is within the
powers of the shareholders.
Section 2. SPECIAL MEETINGS. Special meetings of the shareholders, for any
purpose or purposes whatsoever, may be called at any time by the Board, the
Chairman of the Board, the President, or by the holders of shares entitled to
cast not less than 10% of the votes at the meeting or by such other persons
as may be provided in the Articles or in these Bylaws.
Section 3. NOTICE. Written notice of each meeting shall be given to each
shareholder entitled to vote, either personally or by mail or other means of
written communication, charges prepaid, addressed to such shareholder at his
address appearing on the books of the corporation or given by him to the
Corporation for the purpose of notice. If no such address appears or is
given, notice shall be deemed to have been given to him if sent by mail or
other means of written communication addressed to the place where the
principal executive office of the corporation is situated, or by publication
of notice at least once in some newspaper of general circulation in the
county in which said office is located. All such notices shall be sent to
each shareholder entitled thereto not les than 10 nor more than 60 days before
such meeting. Such notice shall specify the place, the date and the hour of
such meeting.
In the case of a special meeting, the notice shall state the general
nature of business to be transacted and no other business shall be transacted
at such meeting.
In the case of a special meeting called by holders of shares pursuant to
Section 2, the holder or holders shall make a written request to the Chairman
of the Board, President, or Vice President. The written request shall state a
time for the meeting not less than 10 nor more than 60 days after receipt of
<PAGE>
the request. The officer receiving the request shall forthwith cause notice to
be given to each shareholder of the corporation. The notice shall state the
date, time and a place of, and the general nature of the business to be
transacted at, such meeting.
In the case of an annual meeting, the notice shall state those matters
which the Board, at the time of the mailing of the notice, intends to present
for action by the shareholders. However, any proper matter may be present at
the meeting for action but action on the following matters shall be valid only
if the general nature of the proposal so approved was stated in the notice of
the meeting or in a written notice, unless the matter was unanimously
approved by those entitled to vote:
(a) the approval of a contract or other transaction between the
corporation and one or more of its directors or with any corporation, firm or
association in which one or more of its directors has material financial
interest;
(b) an amendment to the Articles;
(c) a reorganization (as defined in Section 181 of the General
Corporation Law) required to be approved by Section 1201 of the
General Corporation Law;
(d) the voluntary winding up and dissolution of the corporation; or
(e) a plan of distribution under Section 2007 of the General Corporation
Law in respect of a corporation in the process of winding up.
The notice of any meeting at which directors are to be elected shall
include the names of the nominees intended at the time of the notice to be
presented by management for election.
The notice shall state such other matters, if any, as may be expressly
required by statute.
Section 4. ADJOURNED MEETING AND NOTICE THEREOF. When a shareholders'
meeting is adjourned to another time or place, notice need not be given of
the adjourned meeting if the time and place thereof are announced at the
meeting at which the adjournment is taken. At the adjourned meeting, the
corporation may transact any business which might have been transacted at the
original meeting. If the adjournment is for more than 45 days or if after the
adjournment a new record date is fixed for the adjourned meeting, a notice of
the adjourned meeting shall be given to each shareholder of record entitled
to vote at the meeting.
-2-
<PAGE>
Section 5. QUORUM. Unless otherwise provided in the Articles, the presence
in person or by proxy of the persons entitled to vote a majority of the
voting shares at any meeting shall constitute a quorum for the transaction of
business. The shareholders present at a duly called or held meeting at which
a quorum is present may continue to transact business until adjournment
notwithstanding the withdrawal of enough shareholders to leave less than a
quorum, if any action taken (other than adjournment) is approved by at least
a majority of the shares required to constitute a quorum. In the absence of a
quorum, any meeting of shareholders may be adjourned from time to time by the
vote of a majority of the shares represented either in person or by proxy,
but no other business may be transacted, except as provided above.
Section 6. CONSENT OF ABSENTEES. The transactions of any meeting of
shareholders, however called and noticed and wherever held are as valid as
though had at a meeting duly held after regular call and notice, if a quorum
is present either in person or by proxy, and if, either before or after the
meeting, each of the persons entitled to vote, not present in person or by
proxy, signs a written waiver of notice, or a consent to the holding of the
meeting, or an approval of the minutes thereof. All such waivers, consents
and approvals shall be filed with the corporate records or made a part of the
minutes of the meeting.
Section 7. ACTION WITHOUT MEETING. Unless otherwise provided in the
Articles, any action which may be taken at any annual or special meeting of
shareholders may be taken without a meeting and without prior notice, if a
consent in writing, setting forth the action so taken, shall be signed by the
holders of outstanding shares having not less than the minimum number of votes
that would be necessary to authorize or take such action at a meeting at which
all shares entitled to vote thereon were present and voted; provided,
however, that:
(a) unless the consents of all shareholders entitled to vote have been
solicited in writing, notice of any shareholder approval:
(1) of a contract of other transaction between the corporation and
one or more of its directors or with any corporation, firm or
association in which one or more of its directors has a
material financial interest;
(2) of an indemnity pursuant to Section 317 of the General
Corporation Law;
-3-
<PAGE>
(3) of a reorganization (as defined in Section 181 of the General
Corporation Law) required to be approved by Section 1201 of the
General Corporation Law; or
(4) of a plan of distribution under Section 2007 of the General
Corporation Law in respect of a corporation in the process of
winding up, which approval was obtained without a meeting by
less than unanimous written consent, shall be given at least
10 days before the consummation of the action authorized by
such approval; and
(b) prompt notice shall be given of the taking of any other corporate
action approved by shareholders without a meeting by less than
unanimous written consent, to those shareholders entitled to vote
who have not consented in writing. Notice of such approval shall be
given in the same manner as required by Article I, Section 3 of
these Bylaws.
Any shareholder giving a written consent, or the shareholder's
proxyholder or proxyholders, or a transferee of the shares, or a personal
representative of the shareholder, or their respective proxyholder or
proxyholders, may revoke the consent by a writing received by the corporation
prior to the time that written consents of the number of shares required to
authorize the proposed action have been filed with the Secretary of the
corporation, but may not do so thereafter. Such revocation is effective upon
its receipt by the Secretary of the corporation.
Notwithstanding the above provisions, directors may not be elected by
written consent except by unanimous written consent of all shares entitled to
vote for the election of directors.
Section 8. RECORD DATES. For purposes of determining the shareholders
entitled to notice of any meeting or to vote or entitled to exercise any
other rights, the Board may fix, in advance, a record date, which shall not
be more than 60 nor less than 10 days prior to the date of such meeting nor
more than 60 days prior to any other action. If no record date is fixed by
the Board:
(a) the record date for determining shareholders entitled to notice of
or to vote at a meeting of shareholders shall be at the close of
business on the business day next preceding the day on which notice
is given or, if notice is waived, at the close of business on the
business day next preceding the day on which the meeting is held;
-4-
<PAGE>
(b) the record date for determining shareholders entitled to give
consent to corporate action in writing without a meeting, when no
prior action by the Board is necessary, shall be the day on which
the first written consent is given; and
(c) the record date for determining shareholders for any other purpose
shall be at the close of business on the day on which the Board
adopts the resolution relating thereto, or the 60th day prior to
the date of such other action, whichever is later. A determination
of shareholders of record entitled to notice of or to vote at a
meeting of shareholders shall apply to any adjournment of the
meeting unless the Board fixes a new record date for the adjourned
meeting, but the Board shall fix a new record date if the meeting
is adjourned for more than 45 days.
Section 9. PROXIES. Every person entitled to vote shares may authorize
another person or persons to act by proxy with respect to such shares. No
proxy shall be valid after the expiration of 11 months from the date thereof
unless otherwise provided in the proxy. Every proxy continues in full force
and effect until revoked as specified in Section 705(b) of the General
Corporation Law or unless it states that it is irrevocable. A proxy which
states that it is irrevocable is irrevocable for the period specified therein
when it is held by a person specified in Section 705(e) of the General
Corporation Law.
Section 10. VOTING; CUMULATIVE VOTING AND NOTICE THEREOF. Votes on any
matter may be VIVA VOCE but shall be by ballot upon demand made by a
shareholder at any election and before the voting begins. No shareholder
shall be entitled to cumulate votes for election of directors (i.e., cast for
any candidate for election as director a number of votes greater than the
number of votes which such shareholder is entitled to cast in votes on
matters other than the election of directors) unless such candidate or
candidates' names have been placed in nomination prior to the voting and the
shareholder has given notice at the meeting prior to the voting of the
shareholder's intention to cumulate the shareholder's votes. If any one
shareholder has given such notice, all shareholders may cumulate their votes
for candidates in nomination. If cumulative voting is proper, every
shareholder entitled to vote at any election of directors may cumulate such
shareholder's votes and give one candidate a number of votes equal to the
number of directors to be elected multiplied by the number of votes to which
the shareholder's shares are normally entitled, or distribute the
shareholder's votes on the same principle among as many candidates as the
shareholder thinks fit. In any election of directors, the candidates
receiving the highest number of votes of the shares
-5-
<PAGE>
entitled to be voted for them up to the number of directors to be elected by
such shares are elected.
Except for election of directors, provided above, votes on other
substantive and procedural matters shall be taken on the basis of one vote
for each shares represented at the meeting.
Fractional shares shall not be entitled to any voting rights.
Section 11. CHAIRMAN OF MEETING. The Board may select any person to preside
as Chairman of any meeting of shareholders, and if such person shall be
absent from the meeting, or fail or be unable to preside, the Board may name
any other person in substitution therefor as Chairman. In the absence of an
express selection by the Board of a Chairman or substitute therefor, the
Chairman of the Board shall preside as Chairman. If the Chairman of the Board
shall be absent, fail or be unable to preside, the President shall preside.
If the President shall be absent, fail or be unable to preside the Vice
President or Vice Presidents in order of their rank as fixed by the Board,
the Secretary, or the Chief Financial Officer, shall preside as Chairman, in
that order. The Chairman of the meeting shall designate a secretary for such
meeting, who shall take and keep or cause to be taken and kept minutes of the
proceedings thereof.
The conduct of all shareholders' meetings shall at all times be within
the discretion of the Chairman of the meeting and shall be conducted under
such rules as he may prescribe. The Chairman shall have the right and power
to adjourn any meeting at any time, without a vote of the shares present in
person or represented by proxy, if the Chairman shall determine such action
to be in the best interests of the corporation and its shareholders.
Section 12. INSPECTORS OF ELECTION. In advance of any meeting of
shareholders, the Board may appoint any persons other than nominees for
office as inspectors of election to act at the meeting and any adjournment
thereof. If inspectors of election are not so appointed, or if any such
persons fail to appear or refuse to act, the Chairman of any such meeting may,
and on the request of any shareholder or his proxy shall, make such
appointment at the meeting. The number of inspectors shall be either one or
three. If appointed at a meeting on the request of one or more shareholders
or proxies, the majority of shares present in person or by proxy shall
determine whether one or three inspectors are to be appointed.
The inspectors of election shall determine the number of shares
outstanding and the voting power of each, the shares represented at the
meeting, the existence of a quorum, the
-6-
<PAGE>
authenticity, validity and effect of proxies, receive votes, ballots or
consents, here and determine all challenges and questions in any way arising
in connection with the right to vote, count and tabulate all votes or
consents, determine when the polls shall close, determine the result and do
such acts as may be proper to conduct the election or vote with fairness to
all shareholders.
If there are three inspectors of election, the decision, act or
certificate of a majority is effective in all respects as the decision, act
or certificate of all.
ARTICLE II
DIRECTORS
Section 1. POWERS. Subject to any limitations in the Articles or these
Bylaws and to any provision of the General Corporation Law relating to action
required to be approved by the shareholders or by the outstanding shares, the
business and affairs of the corporation shall be managed and all corporate
powers shall be exercised by or under the direction of the Board. The Board
may delegate the management of the day-to-day operation of the business of
the corporation to a management company or other person provided that the
business and affairs of the corporation shall be managed and all corporate
powers shall be exercised under ultimate direction of the Board.
Section 2. NUMBER. The authorized number of directors of the Corporation
shall not be less than five (5) nor more than nine (9), the exact number of
directors to be fixed from time to time within such limit by a duly adopted
resolution of the Board of Directors or shareholders. The exact number of
directors presently authorized shall be seven (7) until changed within the
limits specified above by a duly adopted resolution of the Board of Directors
or shareholders.
A Bylaw specifying or changing the fixed number of directors or the
maximum or minimum number of directors or changing from a fixed to a variable
board or vice versa may only be adopted by the vote or the written consent of
shareholders entitled to exercise a majority of the voting power of the
Corporation; provided, however, that a Bylaw or amendment of the Articles
reducing the number or the minimum number of directors to a number less than
five (5) cannot be adopted if the votes cast against its adoption at a
meeting or the shares not consenting in the case of action by written consent
are equal to more than 16-2/3 percent of the shares entitled to vote.
Section 3. ELECTION AND TERM OF OFFICE. The director shall be elected at
each annual meeting of shareholders, and the directors may be elected at any
special meeting of shareholders held for
-7-
<PAGE>
that purpose. Each director, including a director elected to fill a vacancy,
shall hold office until the expiration of the term for which elected or until
a successor has been elected and qualified.
Section 4. ORGANIZATION MEETING. Immediately following each annual meeting
of shareholders the Board shall hold a regular meeting for the purpose of
organization, election of officers, and the transaction of other business.
Section 5. REGULAR MEETINGS. Regular meetings of the Board shall be held at
such times and places within or without the state as may be designated by
resolution of the Board. In the absence or designation of place, regular
meetings shall be held at the principal office of the corporation. The Board
shall hold at least four regular meetings during each fiscal year.
Section 6. SPECIAL MEETINGS. Special meetings of the Board for any purpose
or purposes may be called at any time by the Chairman of the Board, the
President, or by any Vice President or the Secretary or any two directors.
Special meetings of the Board may be held at such times and places within or
without the state as may be designated in the notice of the meeting or which
are designated by resolution of the Board.
Section 7. NOTICE OF MEETINGS. When notice of a meeting of the Board is
required, at lease four days notice by mail or 48 hours notice delivered
personally or by telephone or telegraph shall be given to each director. Such
notice need not specify the purpose of the meeting. Notice of a meeting need
not be given to any director who signs a waiver of notice or consent to
holding the meeting or any approval of the minutes thereof, whether before or
after the meeting, or who attends the meeting without protesting, prior
thereto or at its commencement, the lack of notice to such director. All such
waivers, consents and approvals shall be filed with the corporate records or
made a part of the minutes of the meetings.
Section 8. PARTICIPATION BY TELEPHONE. Members of the Board may participate
in a meeting through use of conference telephone or similar communications
equipment, so long as all members participating in such meeting can hear
one another. Participation in a meeting pursuant to this Section constitutes
presence in person at such meeting.
Section 9. QUORUM. A majority of the authorized number of directors
constitutes a quorum of the Board for the transaction of business. A meeting
at which a quorum is initially present may continue to transact business
notwithstanding the withdrawal of directors, if any action taken is approved
by at least a
-8-
<PAGE>
majority of the required quorum for such meeting. A majority of the directors
present, whether or not quorum is present, may adjourn any meeting to another
time and place.
Section 10. VOTING. Every act or decision done or made by a majority of the
directors present at a meeting duly held at which a quorum is present is the
act of the Board, subject to Section 9 of this Article and to:
(a) the provisions of Section 310 of the General Corporation Law
regarding votes in respect of a contract or other transaction
between the corporation and one or more of its directors or with
any corporation, firm or association in which one or more of its
directors has a material financial interest, and
(b) the provisions of Section 317 of the General Corporation Law
regarding votes in respect of indemnification of agents of the
corporation who are members of the Board.
Section 11. ACTION WITHOUT MEETING. Any action required or permitted to be
taken by the Board may be taken without a meeting if all members of the Board
shall individually or collectively consent in writing to such action. Such
written consent or consents shall be filed with the minutes of the
proceedings of the Board. Such action by written consent shall have the same
force and effect as a unanimous vote of such directors.
Section 12. VALIDATION OF MEETING. The transactions of any meeting of the
Board, however called and noticed or wherever held, shall be as valid as
though had at a meeting duly held after regular call and notice if a quorum
is present and if, either before or after the meeting, each of the directors
not present signs a written waiver of notice, a consent to holding the
meeting or an approval of the minutes thereof. All such waivers, consents and
approvals shall be filed with the corporate records or made a part of
the minutes of the meeting.
Section 13. RESIGNATION. Any director may resign effective upon giving
written notice to the Chairman of he Board, the President, the Secretary of
the Board of the corporation, unless the notice specifies a later time for
the effectiveness of such resignation. If the resignation is effective at a
future time, a successor may be elected to take office when the resignation
becomes effective.
Section 14. VACANCIES. Except for a vacancy created by the removal of a
director, vacancies on the Board may be filled by a majority of the directors
then in office, whether or not less than a quorum, or by a sole remaining
director, vacancies occurring in the Board by reason of the removal of
directors may
-9-
<PAGE>
be filled only by approval of the shareholders. The shareholders may elect a
director at any time to fill any vacancy not filled by the directors. Any
such election by written consent other than to fill a vacancy created by
removal requires the consent of a majority of the outstanding shares entitled
to vote.
No reduction of the authorized number of directors shall have the effect
of removing any director prior to the expiration of his term of office.
Section 15. ADJOURNMENT. A majority of the directors present, whether or not
a quorum is present, may adjourn any meeting to another time and place. If
the meeting is adjourned for more than 24 hours, notice of any adjournment to
another time or place shall be given prior to the time of the adjourned
meeting to the directors who were not present at the time of the adjournment.
Such notice need not comply with the time in which notice must be given prior
to a meeting as required by Section 7 of Article II of the Bylaws, but should
be given as far in advance as is reasonably practicable under all the
circumstances existing at the time of adjournment.
Section 16. VISITORS. No person other than a director may attend any meeting
of the Board without the consent of a majority of the Directors present;
provided, however, that a representative of legal counsel for the corporation
and a representative of the independent certified public accountant for the
corporation may attend any such meeting upon the invitation of any director.
Section 17. FEES AND COMPENSATION. Directors and members of committees may
receive such compensation for their services and such reimbursement for
expenses as may be fixed or determined by resolution of the Board.
Section 18. COMMITTEES. The Board may, by resolution adopted by a majority of
the authorized number of directors, designate one or more committees, each
consisting of two or more directors, to serve at the pleasure of the Board.
The Board may designate one or more directors as alternate members of any
committee, who may replace any absent member at any meeting of the committee.
Any such committee, to the extent provided in the resolution of the Board or
in the Bylaws, shall have all the authority of the Board, except with respect
to:
(a) the approval of any action for which the General Corporation Law
also requires shareholders' approval or approval of the outstanding
shares;
(b) the filling of vacancies on the Board or in any committee;
-10-
<PAGE>
(c) the fixing of compensation of the directors for serving on the
Board or on any committee;
(d) the amendment or repeal of Bylaws or the adoption of new Bylaws;
(e) the amendment or repeal of any resolution of the Board which by its
express terms is not so amendable or repealable;
(f) a distribution to the shareholders of the corporation (as defined
in Section 166 of the General Corporation Law), except at a rate or
in the periodic amount or within a price range determined by the
Board; and
(g) the appointment of other committees of the Board or the members
thereof.
Section 19. MEETINGS AND ACTION OF COMMITTEES. Meetings and action of
committees shall be governed by, and held and taken in accordance with, the
provisions of this Article, Section 5 (Regular Meetings), 6 (Special
Meetings), 7 (Notice of Meetings), 8 (Participation by Telephone), 9
(Quorum), 10 (Voting), 11 (Action Without Meeting), and 15 (Adjournment),
with such changes in the context of those Bylaws as are necessary to
substitute the committee and its members for the Board and its members,
except that the time of regular meetings of committees, special meetings of
committees may also be called by resolutions of the Board and notice of
special meetings of committees shall also be given to all alternate members,
who shall have the right to attend all meetings of the committee. The Board
may adopt rules for the government of any committee not inconsistent with the
provisions of these Bylaws.
ARTICLE III
OFFICERS
Section 1. OFFICERS. The officers of the corporation shall be a Chairman of
the Board or a President, or both, a Secretary and a Chief Financial Officer.
The corporation may also have, at the discretion of the Board, one or more
Vice Presidents, one or more Assistant Secretaries and Assistant Financial
Officers, and such other officers as may be appointed in accordance with the
provision of Section 3 of this Article. One person may hold two or more
offices.
Section 2. ELECTION. The officers of the corporation, except such officers as
may be appointed in accordance with the provisions of Section 3 or Section 5
of this Article, shall be
-11-
<PAGE>
chosen annually by the Board, and each shall hold office until resignation or
removal or other disqualification to serve, or the election of a successor.
Section 3. SUBORDINATE OFFICERS. The Board may appoint, and may empower the
Chairman of the Board or President to appoint, such other officers as the
business of the corporation may require, each of whom shall hold office for
such period, have such authority and perform such duties as are provided in
the Bylaws or as the Board may from time to time determine.
Section 4. REMOVAL AND RESIGNATION. Any officer may be removed, either with or
without cause, by action of the Board duly taken, or, except in case of an
officer chosen by the Board, by any officer upon whom such power of removal
may be conferred by the Board.
Any officer may resign at anytime by giving written notice to the
corporation, to the attention of the Secretary. Any such resignation shall
take effect at the date of the receipt of such notice or at any later time
specified therein; and, unless otherwise specified therein, the acceptance of
such resignation shall not be necessary to make it effective.
Section 5. VACANCIES. A vacancy in any office shall be filled in the manner
prescribed in the bylaws for regular appointments to such office.
Section 6. CHAIRMAN OF THE BOARD. The Chairman of the Board, if there shall be
such an officer, shall, if present, preside at all meetings of the Board,
cause minutes thereof to be taken, and exercise and perform such other powers
and duties as may be from time to time assigned to him by the Board or
prescribed by the Bylaws. In the event the corporation shall not have an
elected President, the Chairman of the Board shall also have the authority and
perform the duties as provided for the President in the following Section of
this Article.
Section 7. PRESIDENT. Subject to such supervisory powers, if any, as may be
given by the Board to the Chairman of the Board, if there is such an officer,
the President shall be the Chief Executive Officer of the corporation and
shall, subject to the control of the Board, have general supervision,
direction and control of the business and officers of the corporation. In the
absence of the Chairman of the Board, or if there is none, the President shall
preside at all meetings of the Board. He shall be ex officio a member of all
the standing committees, including the Executive Committee, if any, and shall
have the general powers and duties of management usually vested in the office
of President of a corporation, and shall have such other powers and duties as
may be prescribed by the Board or the Bylaws.
-12-
<PAGE>
Section 8. VICE PRESIDENT. In the absence or disability of the President,
the Vice Presidents in order of their rank as fixed by the Board or, if not
ranked, the Vice President designated by the Board, shall perform all the
duties of the President, or, if there be none, the Chairman of the Board, and
when so acting shall have all the powers of, and be subject to all the
restrictions upon, the President or Chairman of the Board. The Vice
Presidents shall have such other powers and perform such other duties as from
time to time may be prescribed for each of them by the Board or the Bylaws.
Section 9. SECRETARY. The Secretary shall keep or cause to be kept at the
principal executive office a book of minutes of all meetings and consents to
action without a meeting of directors, committees and shareholders, with the
time and place of holding, whether regular or special, and, if special, how
authorized, the notice thereof given, the names of those present at
directors' and committee meetings, the number of shares present or represented
at shareholder's meetings, and the proceedings thereof.
The Secretary shall keep, or cause to be kept, at the principal
executive office or at the office of the corporation's transfer agent or
registrar, a record of its shareholders showing the names of the shareholders
and their addresses, the number and classes of shares held by each, the
number and date of certificates issued for the same, and the number and date
of cancellation of every certificate surrendered for cancellation.
The Secretary shall give, or cause to be given, notice of all the
meetings of the shareholders and of the Board required by the Bylaws or by
law to be given.
The Secretary shall keep the seal of the corporation in safe custody,
and shall have such other powers and perform such other duties as may be
prescribed by the Board or by the Bylaws.
Section 10. CHIEF FINANCIAL OFFICER. The Chief Financial Officer shall keep
and maintain, or cause to be kept and maintained, adequate and correct
accounts of the properties and business transactions of the corporation,
including changes in financial position, accounts of its assets, liabilities,
receipts, disbursements, gains, losses, capital, surplus and shares. Any
surplus shall be classified according to source and shown in a separate
account.
The Chief Financial Officer shall deposit all monies and other valuables
in the name and to the credit of the corporation with such depositaries as may
be designated by the Board. He shall disburse the funds of the corporation as
may be ordered by
-13-
<PAGE>
the Board or by any officer having authority therefor, shall render to the
President and directors, whenever they request it, an account of all of his
transactions and of the financial condition of the corporation, and shall have
such other powers and perform such other duties as may be prescribed by the
Board or the Bylaws.
ARTICLE IV
MISCELLANEOUS
Section 1. LOANS TO OR GUARANTIES FOR THE BENEFIT OF OFFICERS OR DIRECTORS;
LOANS UPON THE SECURITY OF SHARES OF THE CORPORATION.
(a) Except as expressly provided in subsection (b) hereof, the
corporation shall not make any loan of money or property to our
guarantee the obligation of:
(1) any director or officer of the corporation or of its parent
or any subsidiary, or
(2) any person upon the security of shares of the corporation or of
its parent, unless the loan or guaranty is otherwise adequately
secured, except by the vote of the holders of a majority of
the shares of all classes, regardless of limitations or
restrictions on voting rights, other than shares held by the
benefited director, officer or shareholder.
(b) the corporation may lend money to, or guarantee any obligation of
or otherwise assist any office or other employee of the corporation
or of any subsidiary, including any officer or employee who is also
a director, pursuant to an employee benefit plan (including,
without limitation, any stock purchase or stock option plan)
available to executives or other employees, whenever the Board
determines that such loan or guaranty may reasonably be expected to
benefit the corporation. If such plan includes officers or
directors, it shall be approved by the shareholders after
disclosure of the right under such plan to include officers or
directors thereunder. Such loan or guaranty or other assistance may
be with or without interest and may be unsecured or secured in such
manner as the Board shall approve, including, without limitation, a
pledge of shares of the corporation. The corporation may advance
money to a director or officer of the corporation or of its parent
or any subsidiary for expenses reasonably anticipated to be
incurred in the performance of the duties of such director or
officer, provided that in the absence of such advance
-14-
<PAGE>
such director or officer would be entitled to be reimbursed for such
expenses by such corporation, its parent or any subsidiary.
Section 2. RECORD DATE AND CLOSING STOCK BOOKS. When a record date is
fixed, only shareholders of record on that date are entitled to notice of and
to vote at the meeting or to receive a dividend, distribution, or allotment
of rights, or to exercise the rights, as the case may be, notwithstanding any
transfer of any shares on the books of the corporation after the record date.
The Board may close the books of the corporation against transfers of
shares during the whole or any part of a period not more than 60 days prior
to the date of a shareholders' meeting, the date when the right to any
dividend, distribution, or allotment of rights vests, or the effective date of
any change, conversion or exchange of shares.
Section 3. INSPECTION OF CORPORATE RECORDS. The record of shareholders, the
accounting books and records of the corporation, and minutes of proceedings
of the shareholders, the Board and committees of the Board shall be open to
inspection upon the written demand of any shareholder or holder of a voting
trust certificate, at any time during usual business hours for a purpose
reasonably related to his interests as a shareholder or as the holder of a
voting trust certificate. Such inspection may be made in person or by a agent
or attorney, and shall include the right to copy and make extracts. Demand
of inspection shall be made in writing upon the corporation to the attention
of the Secretary.
A shareholder or shareholders holding at least five percent in the
aggregate of the outstanding voting shares of the corporation or who hold at
least one percent of such voting shares and have filed a Schedule 14-B with
the United States Securities and Exchange Commission relating to the election
of directors of the corporation shall have an absolute right to access to a
list of shareholders as provided in section 1600(a) of the General Corporation
Law.
Section 4. EXECUTION OF CONTRACTS. Any contract or other instrument in
writing entered into by the corporation, when signed by the Chairman of the
Board, the President or any Vice President and the Secretary, and Assistant
Secretary, the Chief Financial Officer or any Assistant Financial Officer or
any Assistant Financial Officer is not invalidated as to the corporation by
any lack of authority of the signing officers in the absence of actual
knowledge on the part of the other party to the contract or other instrument
that the signing officers had no authority to execute the same. Contracts or
other instruments in writing made in the name of the corporation which are
authorized or ratified by the Board, or are
-15-
<PAGE>
done within the scope of authority, actual or apparent, conferred by the Board
or within the agency power of the officer executing it, bind the corporation.
Section 5. SHARE CERTIFICATES. A certificate or certificates for shares of
the capital stock of the corporation shall be issued to each shareholder when
any such shares are fully paid. Every shareholder in the corporation shall be
entitled to have a certificate signed in the name of the corporation by the
Chairman of the Board or the President or a Vice President and by the Chief
Financial Officer or an Assistant Financial Officer or the Secretary or any
Assistant Secretary, certifying the number of shares and the class or series
of shares owned by the shareholders. Any or all of the signatures on the
certificate may be facsimile.
The corporation may issue the whole or any part of its shares as partly
paid and subject to call for the remainder of the consideration to be paid
therefor. On the certificates issued to represent any partly paid shares the
total amount of the consideration to be paid therefor and the amount paid
thereon shall be stated.
No new certificate for shares shall be issued in lieu of an old
certificate unless the latter is surrendered and cancelled at the same time;
provided, however, that a new certificate may be issued without the surrender
and cancellation of the old certificate if:
(a) the old certificate is lost, stolen or destroyed:
(b) the request for the issuance of the new certificate is made within a
reasonable time after the owner of the old certificate has notice
of its loss, destruction, or theft;
(c) the request for the issuance of a new certificate is made prior to
the receipt of notice by the corporation that the old certificate has
been acquired by a bona fide purchaser; and
(d) the owner satisfies any other reasonable requirements imposed by the
corporation including, at the election of the Board, the filing of
sufficient indemnity bond or undertaking with the corporation or its
transfer agent. In the event of the issuance of a new certificate,
the rights and liabilities of the corporation, and of the holders
of the old and new certificates, shall be governed by the provisions
of Sections 8014 and 8405 of the California Commercial Code.
-16-
<PAGE>
Section 6. REPRESENTATION OF SECURITIES OF OTHERS. Unless otherwise
determined by the Board or the Executive Committee, the President, or any
other officer of the corporation designated in writing by the President, is
authorized to vote, represent and exercise on behalf of the corporation all
rights incident to any and all securities of any other person or entity
standing in the name of the corporation. The authority herein granted may be
exercised either in person, or by proxy.
Section 7. INSPECTION OF BYLAWS. The corporation shall keep in its
principal executive or business office in this state, the original or a copy
of its Bylaws as amended to date, which shall be open to inspection by the
shareholders at all reasonable times during the officer hours.
Section 8. EMPLOYEE STOCK PURCHASE PLAN AND OPTION PLANS. The corporation
may adopt and carry out a stock purchase plan or agreement or stock option
plan or agreement providing for the issuance and sale for such consideration
as may be fixed of its unissued shares, or of issued shares acquired or to be
acquired, to one or more of the employees or directors of the corporation or
of a subsidiary or to a trustee on their behalf and for the payment for such
shares in installments or at one time, and may provide for aiding any such
person in paying for such shares by compensation for services rendered,
promissory notes or otherwise.
A stock purchase plan or agreement or stock option plan or agreement may
include, among other features, the fixing of eligibility for participation
therein, the class and price of shares to be issued or sold under the plan or
agreement, the number of shares which may be subscribed for, the method of
payment therefor, the reservation of title until full payment therefor, the
effect of the termination of employment, an option or obligation on the part
of the Corporation to repurchase the shares upon termination of employment,
subject to the provisions of Chapter 5 of the California Corporations Code,
restrictions upon transfer of the shares and the time limits of and
termination of the plan.
Section 9. CONSTRUCTION AND DEFINITIONS. Unless the context otherwise
requires, the general provisions, rules of construction and definitions
contained in the California General Corporation Law shall govern the
construction of these Bylaws. Without limiting the generality of the
foregoing, the masculine gender includes the feminine and neuter, the
singular number includes the plural and the plural number includes the
singular, and the term "person" includes a corporation as well as a natural
person.
Section 10. INDEMNIFICATION OF CORPORATE AGENTS. The corporation shall have
power to indemnify any person who is or
-17-
<PAGE>
was an agent of the corporation as provided in Section 317 of the California
General Corporation Law.
Section 11. FINANCIAL STATEMENTS. A copy of any annual financial statement
and any income statement of the corporation for each quarterly period of each
fiscal year, and any accompanying balance sheet of the corporation as of the
end of each such period, that has been prepared by the corporation shall be
kept on file in the principal executive office of the corporation for 12
months and each such statement shall be exhibited at all reasonable times to
any shareholder demanding an examination of any such statement or a copy
shall be mailed to any such shareholder.
A shareholder or shareholders holding at least five percent of the
outstanding shares of any class of stock of the corporation may make a
written request to the corporation for an income statement of the corporation
for the three-month, six-month or nine-month period of the then current
fiscal year ended more than 30 days prior to the date of the request, and a
balance sheet of the corporation as of the end of such period; the Chief
Financial officer shall cause such statements to be prepared, if not already
prepared, and shall deliver personally or mail such statements to the person
making the request within 30 days after the receipt of such request. If the
corporation has not sent to the shareholders its annual report for the last
fiscal year, this report shall likewise be delivered or mailed to such
shareholder or shareholders within 30 days after such request.
The corporation also shall, upon the written request of any shareholder,
mail to the shareholder a copy of the last annual, semi-annual or quarterly
income statement which it has prepared and a balance sheet as of the end of
such period.
The quarterly income statements and balance sheets referred to in this
section shall be accompanied by the report thereon, if any, of any
independent accountants engaged by the corporation or the certificate of an
authorized officer of the corporation that such financial statements were
prepared without audit from the books and records of the corporation.
Section 12. CHECKS, DRAFTS, EVIDENCES OF INDEBTEDNESS. All checks, drafts or
other orders for payment of money, notes or other evidences of indebtedness,
issued in the name of or payable to the corporation, shall be signed or
endorsed by such person or persons and in such manner as, from time to time,
shall be determined by resolution of the Board.
-18-
<PAGE>
ARTICLE V
AMENDMENTS TO BYLAWS
Section 1. POWER OF SHAREHOLDERS. Bylaws may be adopted, amended, or repealed
by the vote or the written consent of shareholders entitled to exercise a
majority of the voting power of the corporation. Subject to the right of
shareholders to adopt, amend or repeal Bylaws, Bylaws may be adopted,
amended, or repealed by the Board of Directors, except that a Bylaw
specifying or changing a fixed number of directors or the maximum or minimum
number of directors, may only be adopted by the vote or the written consent
of shareholders entitled to exercise a majority of the voting power of the
Corporation.
Section 2. EFFECTIVE DATE. These Restated Bylaws shall be effective for all
purposes on January 25, 1990.
-19-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AND STATEMENT OF OPERATIONS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> SEP-30-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 381
<SECURITIES> 7781
<RECEIVABLES> 1062
<ALLOWANCES> (10)
<INVENTORY> 2833
<CURRENT-ASSETS> 12606
<PP&E> 8522
<DEPRECIATION> (7692)
<TOTAL-ASSETS> 13664
<CURRENT-LIABILITIES> 4704
<BONDS> 0
0
0
<COMMON> 102392
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 13664
<SALES> 2561
<TOTAL-REVENUES> 2767
<CGS> 1486
<TOTAL-COSTS> 1567
<OTHER-EXPENSES> 4067
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (243)
<INCOME-PRETAX> (2,624)
<INCOME-TAX> 0
<INCOME-CONTINUING> (2,624)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,624)
<EPS-PRIMARY> (.03)
<EPS-DILUTED> 0
</TABLE>
